Phase-I/II biotransformation
What is Phase-I/II biotransformation?
Phase-I/II biotransformation testing measures how skin models convert selected foreign organic compounds into metabolites. Tracking the parent compound and reaction products helps determine whether an ingredient changes metabolic conversion, rather than relying only on enzyme-expression markers.
Why do you need this service?
Biotransformation studies investigate conversion of selected organic compounds into metabolites in skin models. Use them to distinguish changes in metabolic conversion from changes in enzyme expression alone.
Be the first company on this service page
No published company profiles are linked to Phase-I/II biotransformation or its more specific services yet. Explore the service categories or add an explicitly supported capability to your company profile.
Phase-I/II biotransformation
Biotransformation studies investigate what happens to a defined xenobiotic in a skin-cell or enzyme system. They focus on the conversion of the parent compound and formation of metabolites, complementing assays that measure enzyme induction alone.
Following metabolic conversion
Phase I reactions can modify an organic compound through oxidation or related processes. Phase II reactions can attach groups through pathways such as glutathione conjugation or glucuronidation. These processes do not necessarily occur as a mandatory sequence.
- Parent-compound levels before and after exposure
- Formation of identifiable metabolites or conjugates
- Relevant enzyme activity alongside chemical measurements
- Cell viability under the selected challenge conditions
Cytochrome P450, glutathione S-transferase, and UDP-glucuronosyltransferase measurements can help interpret the observed conversion.
Interpreting protection and clearance
Conversion is not automatically detoxification: a metabolite may be less harmful, similarly active, or more reactive than its precursor. A clearance claim also needs evidence of removal or export, not simply a lower parent-compound signal.
Metals are not broken down by Phase I/II metabolism, and particulate mixtures require chemically defined endpoints. Reports should specify the substrate, model, metabolites measured, and limits of detection. This service supports a focused account of xenobiotic handling rather than generalized cellular cleanup claims.
Investigating conversion of a defined compound
Specify the parent compound and the metabolic question before selecting a challenge. Phase I and Phase II work can examine relevant enzyme pathways together with parent-compound and metabolite measurements. Expression changes help describe a response but do not establish the rate or direction of conversion.
Pollution-related research needs a defined chemical exposure. Metal ions are not broken down by organic biotransformation pathways, and a particulate mixture cannot be treated as one metabolically uniform substance. Metal-binding or particle-removal questions require a different scope.
Interpret conversion alongside viability and relevant damage endpoints. Greater metabolism may produce harmful as well as less harmful products. Report actual findings rather than assigning an expected detoxification percentage or claiming whole-body pollutant clearance.
Investigate xenobiotic responses and cellular clearance through metabolism, autophagy and protein turnover studies with endpoint-specific interpretation. Explore another Xenobiotic & Cellular Clearance Studies page on cosmetic-labs.com.